Recently, TroClose™ 2.0, a Class III innovative medical device for which Lujian Technology holds global exclusive manufacturing rights and exclusive commercial operation rights in China, successfully completed production and quality testing at Sichuan Innovation Technology Co., Ltd. in Chengdu and is ready for launch. This marks a major milestone toward global commercialization and signals the start of the product’s U.S. market launch plan.
TroClose™ 2.0 transforms closure from a “manual skill” into a “standardized process” through its unique technological pathway. Each operation is made as consistent as possible, reducing the incidence of incisional hernia at puncture sites to 0% while significantly lowering postoperative pain, meeting higher clinical standards for surgical closure devices.
Next, the project team, in collaboration with Qingdao Lujian and other partners, will work with the Surgical Advisory Board and the clinical research team of Allegheny Health Network (AHN) to publish the first paper on this technology in partnership with Intuitive Surgical, supporting comprehensive market promotion.
At the same time, we will continue to provide in-depth clinical support and market development for the TroClose product series, actively advancing their registration process in China, aiming to bring this cutting-edge technology to domestic operating rooms as soon as possible, serving surgeons and patients nationwide.
In the future, Lujian Technology will continue to focus on the introduction and localization of high-value innovative medical devices, bridging international technologies with China’s clinical needs, and leveraging its global strategy and professional service capabilities to promote high-quality development of the healthcare industry.
WeChat Official Account |
Video Channel |
